Oxigene Inc (OXGN) 0.70 $OXGN OXiGENE Announces
Post# of 273258
Posted On: 09/02/2016 7:21:57 AM
Oxigene Inc (OXGN) 0.70 $OXGN
OXiGENE Announces Name Change to Mateon Therapeutics
GlobeNewswire - Fri Jun 17, 9:15AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology indications, today announced that it has changed its name to Mateon Therapeutics, Inc., effective immediately. On the NASDAQ Capital Market, the name change will be effective for trading purposes as of market open on June 20, 2016. At that time, shares of Mateon's common stock will begin trading under the new ticker symbol "MATN". In connection with the name change, Mateon's common stock has been assigned a new CUSIP number of 57667K109.
OXGN: 0.70 (-0.03)
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma
GlobeNewswire - Fri Jun 10, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of glioma. The designation provides for seven years of marketing exclusivity following product approval. CA4P has previously received orphan drug designation from the FDA for the treatment of ovarian cancer, neuroendocrine tumors and certain thyroid cancers.
OXGN: 0.70 (-0.03)
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology
GlobeNewswire - Tue May 24, 5:30AM CDT
Study met primary endpoint of improvement in progression free survival
OXGN: 0.70 (-0.03)
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GlobeNewswire - Fri May 20, 5:00AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS" pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease ("PD", today announced the appointment of Frederick W. Driscoll to its board of directors, effective May 20, 2016. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Mr. Driscoll will also serve on Cynapsus' audit committee.
OXGN: 0.70 (-0.03), FLXN: 16.91 (+0.23), CYNA: 39.70 (+21.34), CTH.TO: 51.98 (+27.50)
OXiGENE Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 7:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today reported financial results for the first quarter of 2016.
OXGN: 0.70 (-0.03)
Oxigene Receives Fast Track Designation From U.S. FDA for CA4P
GlobeNewswire - Wed Mar 30, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CA4P for the treatment of platinum-resistant ovarian cancer. Companies with Fast Track designation are able to benefit from more frequent meetings and communications with the FDA regarding development plans to support product registration, and may also be eligible for priority review of New Drug Applications, which shortens FDA's standard review timeline.
OXGN: 0.70 (-0.03)
OXiGENE Reports 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for 2015.
OXGN: 0.70 (-0.03)
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
GlobeNewswire - Fri Mar 25, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tumors (NETs). The designation provides for ten years of marketing exclusivity in European Union (EU) member countries following product approval. Earlier this year OXiGENE announced that CA4P received orphan drug designation from the U.S. Food and Drug Administration for NETs, which provides for seven years of marketing exclusivity after approval.
OXGN: 0.70 (-0.03)
OXiGENE Appoints Dr. Simon Pedder to Board of Directors
GlobeNewswire - Thu Mar 24, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that Simon C. Pedder, Ph.D. has been appointed to OXiGENE's board of directors, effective March 21, 2016.
OXGN: 0.70 (-0.03)
OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update
GlobeNewswire - Wed Feb 03, 8:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced it will present a company overview on February 8, 2016 at 11:30 a.m. Eastern time at the 2016 BIO CEO & Investor Forum.
OXGN: 0.70 (-0.03)
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
GlobeNewswire - Wed Jan 06, 7:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors. The designation provides for seven years of marketing exclusivity following product approval. CA4P has previously received orphan drug designation from the FDA for the treatment of ovarian cancer.
OXGN: 0.70 (-0.03)
OXiGENE passes European Commission's orphan drug designation for OXi4503 for Acute Myeloid Leukemia
M2 - Fri Dec 18, 3:10AM CST
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) reported on Thursday that it has received European Commission orphan drug designation for OXi4503 for the treatment of acute myeloid leukemia (AML).
OXGN: 0.70 (-0.03)
OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia
GlobeNewswire - Thu Dec 17, 2:00PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML). The designation provides for ten years of marketing exclusivity in EU member countries following product approval. OXi4503 has previously received orphan drug designation from the U.S. Food and Drug Administration, which provides for seven years of marketing exclusivity after approval.
OXGN: 0.70 (-0.03)
OXiGENE Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 10, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015.
OXGN: 0.70 (-0.03)
OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
GlobeNewswire - Thu Nov 05, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient(TM) (pazopanib) in patients with advanced recurrent ovarian cancer. The data are from the ongoing "PAZOFOS" study and were presented at the 19 International Meeting of the European Society of Gynaecological Oncology (ESGO) in Nice, France.
OXGN: 0.70 (-0.03)
OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia
GlobeNewswire - Wed Oct 21, 3:15PM CDT
-- First patient dosed in OXiGENE-sponsored expansion of investigator trial
OXGN: 0.70 (-0.03)
OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors
GlobeNewswire - Mon Oct 19, 7:00AM CDT
-- Biomarker results in first nine subjects add to CA4P evidence of activity --
OXGN: 0.70 (-0.03)
OXiGENE to Present at the 14th Annual BIO Investor Forum
GlobeNewswire - Fri Oct 16, 11:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it will present a company overview at the 14 Annual BIO Investor Forum. The BIO Investor Forum will be held October 20-21 at the Parc 55 Hotel in San Francisco. OXiGENE is scheduled to present on Tuesday, October 20 at 4:00 pm Pacific time.
OXGN: 0.70 (-0.03)
Investors look to Lighten Up on Shares of OXiGENE, Shares Down 6.5% (OXGN)
Comtex SmarTrend(R) - Thu Oct 01, 10:43AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's worst performing penny stocks, down 6.5% to $0.87 on 2.5x average daily volume. OXiGENE has traded 551,000 shares thus far today, vs. average volume of 223,000 shares per day. The stock has underperformed the Dow (-6.5% to the Dow's -0.6%) and underperformed the S&P 500 (-6.5% to the S&P's -0.3%) during today's trading.
OXGN: 0.70 (-0.03)
OXiGENE (OXGN) to Initiate Two Phase II/III Studies on CA4P
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 4:54PM CDT
OXiGENE (OXGN) announced that its plans to conduct two phase II/III randomized studies on CA4P for the treatment of ovarian cancer and glioblastoma multiforme.
OXGN: 0.70 (-0.03), EBS: 26.41 (-0.24), NVET: 4.03 (-0.02), REGN: 393.40 (+0.85)
OXiGENE Announces Name Change to Mateon Therapeutics
GlobeNewswire - Fri Jun 17, 9:15AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology indications, today announced that it has changed its name to Mateon Therapeutics, Inc., effective immediately. On the NASDAQ Capital Market, the name change will be effective for trading purposes as of market open on June 20, 2016. At that time, shares of Mateon's common stock will begin trading under the new ticker symbol "MATN". In connection with the name change, Mateon's common stock has been assigned a new CUSIP number of 57667K109.
OXGN: 0.70 (-0.03)
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma
GlobeNewswire - Fri Jun 10, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of glioma. The designation provides for seven years of marketing exclusivity following product approval. CA4P has previously received orphan drug designation from the FDA for the treatment of ovarian cancer, neuroendocrine tumors and certain thyroid cancers.
OXGN: 0.70 (-0.03)
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology
GlobeNewswire - Tue May 24, 5:30AM CDT
Study met primary endpoint of improvement in progression free survival
OXGN: 0.70 (-0.03)
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
GlobeNewswire - Fri May 20, 5:00AM CDT
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system ("CNS" pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease ("PD", today announced the appointment of Frederick W. Driscoll to its board of directors, effective May 20, 2016. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. Mr. Driscoll will also serve on Cynapsus' audit committee. OXGN: 0.70 (-0.03), FLXN: 16.91 (+0.23), CYNA: 39.70 (+21.34), CTH.TO: 51.98 (+27.50)
OXiGENE Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 7:00AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today reported financial results for the first quarter of 2016.
OXGN: 0.70 (-0.03)
Oxigene Receives Fast Track Designation From U.S. FDA for CA4P
GlobeNewswire - Wed Mar 30, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CA4P for the treatment of platinum-resistant ovarian cancer. Companies with Fast Track designation are able to benefit from more frequent meetings and communications with the FDA regarding development plans to support product registration, and may also be eligible for priority review of New Drug Applications, which shortens FDA's standard review timeline.
OXGN: 0.70 (-0.03)
OXiGENE Reports 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for 2015.
OXGN: 0.70 (-0.03)
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
GlobeNewswire - Fri Mar 25, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tumors (NETs). The designation provides for ten years of marketing exclusivity in European Union (EU) member countries following product approval. Earlier this year OXiGENE announced that CA4P received orphan drug designation from the U.S. Food and Drug Administration for NETs, which provides for seven years of marketing exclusivity after approval.
OXGN: 0.70 (-0.03)
OXiGENE Appoints Dr. Simon Pedder to Board of Directors
GlobeNewswire - Thu Mar 24, 7:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that Simon C. Pedder, Ph.D. has been appointed to OXiGENE's board of directors, effective March 21, 2016.
OXGN: 0.70 (-0.03)
OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update
GlobeNewswire - Wed Feb 03, 8:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced it will present a company overview on February 8, 2016 at 11:30 a.m. Eastern time at the 2016 BIO CEO & Investor Forum.
OXGN: 0.70 (-0.03)
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
GlobeNewswire - Wed Jan 06, 7:00AM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors. The designation provides for seven years of marketing exclusivity following product approval. CA4P has previously received orphan drug designation from the FDA for the treatment of ovarian cancer.
OXGN: 0.70 (-0.03)
OXiGENE passes European Commission's orphan drug designation for OXi4503 for Acute Myeloid Leukemia
M2 - Fri Dec 18, 3:10AM CST
Biopharmaceutical company OXiGENE (NasdaqCM:OXGN) reported on Thursday that it has received European Commission orphan drug designation for OXi4503 for the treatment of acute myeloid leukemia (AML).
OXGN: 0.70 (-0.03)
OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia
GlobeNewswire - Thu Dec 17, 2:00PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML). The designation provides for ten years of marketing exclusivity in EU member countries following product approval. OXi4503 has previously received orphan drug designation from the U.S. Food and Drug Administration, which provides for seven years of marketing exclusivity after approval.
OXGN: 0.70 (-0.03)
OXiGENE Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 10, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015.
OXGN: 0.70 (-0.03)
OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
GlobeNewswire - Thu Nov 05, 3:15PM CST
OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient(TM) (pazopanib) in patients with advanced recurrent ovarian cancer. The data are from the ongoing "PAZOFOS" study and were presented at the 19 International Meeting of the European Society of Gynaecological Oncology (ESGO) in Nice, France.
OXGN: 0.70 (-0.03)
OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia
GlobeNewswire - Wed Oct 21, 3:15PM CDT
-- First patient dosed in OXiGENE-sponsored expansion of investigator trial
OXGN: 0.70 (-0.03)
OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors
GlobeNewswire - Mon Oct 19, 7:00AM CDT
-- Biomarker results in first nine subjects add to CA4P evidence of activity --
OXGN: 0.70 (-0.03)
OXiGENE to Present at the 14th Annual BIO Investor Forum
GlobeNewswire - Fri Oct 16, 11:30AM CDT
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it will present a company overview at the 14 Annual BIO Investor Forum. The BIO Investor Forum will be held October 20-21 at the Parc 55 Hotel in San Francisco. OXiGENE is scheduled to present on Tuesday, October 20 at 4:00 pm Pacific time.
OXGN: 0.70 (-0.03)
Investors look to Lighten Up on Shares of OXiGENE, Shares Down 6.5% (OXGN)
Comtex SmarTrend(R) - Thu Oct 01, 10:43AM CDT
OXiGENE (NASDAQ:OXGN) is one of today's worst performing penny stocks, down 6.5% to $0.87 on 2.5x average daily volume. OXiGENE has traded 551,000 shares thus far today, vs. average volume of 223,000 shares per day. The stock has underperformed the Dow (-6.5% to the Dow's -0.6%) and underperformed the S&P 500 (-6.5% to the S&P's -0.3%) during today's trading.
OXGN: 0.70 (-0.03)
OXiGENE (OXGN) to Initiate Two Phase II/III Studies on CA4P
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 4:54PM CDT
OXiGENE (OXGN) announced that its plans to conduct two phase II/III randomized studies on CA4P for the treatment of ovarian cancer and glioblastoma multiforme.
OXGN: 0.70 (-0.03), EBS: 26.41 (-0.24), NVET: 4.03 (-0.02), REGN: 393.40 (+0.85)
(0)
(0)Scroll down for more posts ▼